NanoVelcro Chip for CTC enumeration in prostate cancer patients

Lu, Yi‐Tsung; Zhao, Libo; Shen, Qinglin; Garcia, Mitch A.; Wu, Danni; Hou, Shuang; Song, Min; Xu, Xiaochun; OuYang, Wei‐Han; OuYang, William; Lichterman, Jake; Luo, Zheng; Xuan, Xuan; Huang, Jiaoti; Chung, Leland W.K.; Rettig, Matthew B.; Tseng, Hsian‐Rong; Shao, Chen; Posadas, Edwin M.

doi:10.1016/j.ymeth.2013.06.019

Cited by 113 publications

(139 citation statements)

References 29 publications

Supporting

Mentioning

134

Contrasting

Order By: Relevance

“…Nagrath et al (2007) developed a unique microfluidic platform (the 'CTC-chip') capable of efficient separation of CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115-116 (99%) samples, with a range of 5-1281 CTCs/ml and approximately 50% purity. Lu et al (2013) described a nanovelcro chip for CTC enumeration in PCa patients. The CTCs were captured with high efficiency of 1-99/ml.…”

Section: Ctcs Detection On Lapsmentioning

confidence: 99%

“…Nanomaterials (e.g. nanoparticles, nanowires, and nanotubes) provide exciting new opportunities to improve CTCs detection efficiency (Lu et al, 2013;Wang et al, 2013). Graphene oxide (GO), a promising precursor of graphene, offers great potential for biological sensing because of its unique characteristics such as facile surface modification, good water dispersibility, and photoluminescence (Jung et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of circulating tumor cells in prostate cancer based on carboxylated graphene oxide modified light addressable potentiometric sensor

Cheng

et al. 2015

Biosensors and Bioelectronics

View full text Add to dashboard Cite

Section: Ctcs Detection On Lapsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Detection of circulating tumor cells in prostate cancer based on carboxylated graphene oxide modified light addressable potentiometric sensor

Cheng

et al. 2015

Biosensors and Bioelectronics

View full text Add to dashboard Cite

“…The NanoVelcro microfluidic device incorporates anti- EpCAM-antibody-coated silicon nanowires with an overlaid polydimethylsiloxane chaotic mixer to generate vertical flows, and enhances contacts between CTCs and the capture substrate 43 . The NanoVelcro device has demonstrated its consistency for CTC enumeration in metastatic prostate cancer and established that continuous monitoring of CTC enumeration could be employed to examine disease progression and to follow prostate cancer patients’ responses to different treatments 43 .…”

Section: Methods: Ctc Isolation Approaches and Molecular Characterizamentioning

confidence: 99%

“…The NanoVelcro device has demonstrated its consistency for CTC enumeration in metastatic prostate cancer and established that continuous monitoring of CTC enumeration could be employed to examine disease progression and to follow prostate cancer patients’ responses to different treatments 43 .…”

Section: Methods: Ctc Isolation Approaches and Molecular Characterizamentioning

confidence: 99%

Using circulating tumor cells to inform on prostate cancer biology and clinical utility

Gregory

García-Blanco

et al. 2015

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

Substantial advances in the molecular biology of prostate cancer have led to the approval of multiple new systemic agents to treat men with metastatic castration-resistant prostate cancer (mCRPC). These treatments encompass androgen receptor directed therapies, immunotherapies, bone targeting radiopharmaceuticals and cytotoxic chemotherapies. There is, however, great heterogeneity in the degree of patient benefit with these agents, thus fueling the need to develop predictive biomarkers that are able to rationally guide therapy. Circulating tumor cells (CTCs) have the potential to provide an assessment of tumor-specific biomarkers through a non-invasive, repeatable “liquid biopsy” of a patient’s cancer at a given point in time. CTCs have been extensively studied in men with mCRPC, where CTC enumeration using the Cellsearch® method has been validated and FDA approved to be used in conjunction with other clinical parameters as a prognostic biomarker in metastatic prostate cancer. In addition to enumeration, more sophisticated molecular profiling of CTCs is now feasible and may provide more clinical utility as it may reflect tumor evolution within an individual particularly under the pressure of systemic therapies. Here, we review technologies used to detect and characterize CTCs, and the potential biological and clinical utility of CTC molecular profiling in men with metastatic prostate cancer.

show abstract

“…A number of devices, following CellSearch® system, have immobilized anti-EpCAM antibodies on the surface of various microuidic devices and successfully isolated cancer cells that show high-EpCAM expressions. [7][8][9][10][11][12] However, considering that EpCAM expression is down-regulated aer cells experience epithelial-tomesenchymal transition (EMT), the method using antiEpCAM antibody might miss some of the CTC subtypes that are more invasive and directly related to the metastasis. 13 Other antibodies have been suggested to target these malignant CTC subtypes, including vimentin, MUC1, and CAV1.…”

mentioning

confidence: 99%

Enhancement of isolation sensitivity for the viable heterogeneous circulating tumor cells swelled by hypo-osmotic pressure

Cho

Han

2017

RSC Adv.

View full text Add to dashboard Cite

We present a viable circulating tumor cell (CTC) isolation method based on hypo-osmotic swelling, which is applicable to various size-based CTC isolation devices. The previous CTC filtration devices suffered from the size overlap between CTCs and large leukocytes. Affinity-based size enhancement has been employed to separate CTCs and leukocytes with similar sizes, but the size enhancement was confined to the CTCs expressing specific surface proteins and the cell loss or viability reduction was inevitable when detaching the antibody-conjugated beads from the captured CTCs. In contrast, hypo-osmotic swelling is applicable regardless of the cancer cell types. The size increments of both epithelial-and mesenchymallike cancer cells were larger than that of leukocytes, with less than 10% of cell death at the osmolality of 190 mOsm kg À1. Consequently, cancer cell isolation was 1.2-fold enhanced with negligible reduction in specificity or cell viability, when using one of the conventional CTC filters. We further explored the improvements in CTC isolation using patients' blood samples and confirmed that the CTC detection rate was enhanced when the samples were processed under hypotonic conditions. Our label-free cell size increment technique can be widely applied to the various CTC filters, for enhancing the isolation of heterogeneous CTCs. IntroductionMetastasis is the leading cause of death among cancer patients, since over 90% of human deaths due to cancer are strongly associated with metastasis. 1Tumour metastasis involves a series of processes, including invasion of a proliferative tumour into the surrounding blood vessels, intravasation of the tumour cells into the blood stream, and the secondary tumour formation aer extravasation of the detached tumour cells. 2Circulating tumour cells (CTCs) are the cells that have been detached from the primary tumour and circulate through the peripheral blood during the metastasis. It has been reported that the number and the characteristic of CTCs highly match with the malignancy of a tumor. 3,4 In this regard, CTCs have huge potential as novel biomarkers that not only allow early diagnosis of a tumour but also provide evaluation of treatment effectiveness. 5A number of CTC isolation methods have been developed by the advance in microuidics. Two of the most widely accepted CTC isolation methods are the method based on markerspecic binding and the method utilizing the difference in size or other physical properties between CTCs and other blood cells.6 The affinity-based CTC isolation method relies on the binding force between antibody and specic antigen, which is widely expressed on the surface of CTCs. The only FDA-approved CTC detection system, CellSearch®, also enumerates CTCs using the antibody against epithelial cell adhesion molecule (EpCAM). A number of devices, following CellSearch® system, have immobilized anti-EpCAM antibodies on the surface of various microuidic devices and successfully isolated cancer cells that show high-EpCAM expressions.7-12 However, conside...

show abstract

NanoVelcro Chip for CTC enumeration in prostate cancer patients

Cited by 113 publications

References 29 publications

Detection of circulating tumor cells in prostate cancer based on carboxylated graphene oxide modified light addressable potentiometric sensor

Detection of circulating tumor cells in prostate cancer based on carboxylated graphene oxide modified light addressable potentiometric sensor

Using circulating tumor cells to inform on prostate cancer biology and clinical utility

Enhancement of isolation sensitivity for the viable heterogeneous circulating tumor cells swelled by hypo-osmotic pressure

Contact Info

Product

Resources

About